聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者疗效及对血清细胞因子和肝纤维化指标的影响

doi:10.3969/j.issn.1672-5069.2016.05.006

摘要/Abstract

摘要： 目的观察聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性的慢性乙型肝炎（CHB）患者的疗效及其对血清T淋巴细胞因子和肝纤维化指标的影响。方法144例CHB患者依纳入顺序单双号被随机分为观察组和对照组,每组72例。给予对照组患者阿德福韦酯,观察组在对照组的基础上给予聚乙二醇干扰素α-2a,治疗24 w,观察两组抗病毒疗效以及血清T淋巴细胞因子白介素（IL）-2、IL-6、IL-10、γ-干扰素（INF-γ）以及血清肝纤维化指标Ⅲ型前胶原肽（PⅢP）、层粘连蛋白（LN）、透明质酸（HA）、Ⅳ型胶原(Ⅳ-C）的变化。结果在治疗24 w末,观察组患者血清HBV 转阴率、HBeAg转阴率、HBeAg血清转换率分别为72.22%、58.33%和41.67%,显著高于对照组(分别为55.56%、22.22%和20.83%,P<0.05）;观察组血清IL-2和INF-γ水平分别为（2.18±1.26） pg/ml和（99.65±11.03） pg/ml,较对照组显著升高【（1.71±1.05） pg/ml和（85.70±11.82） pg/ml,P<0.05】,而IL-6和IL-10分别为（4.53±2.15） pg/ml和（15.42±9.39） pg/ml,较对照组显著降低【（5.47±2.25） pg/ml和（20.07±13.08）pg/ml,P<0.05】;观察组HA、LN、Ⅳ-C、PⅢP分别为（127.28±59.60） μg/L、（110.52±37.39） μg/L、（116.56±28.61） μg/L和（163.65±64.38） μg/L,均较对照组显著降低【（261.35±81.46） μg/L、（162.32±38.82）μg/L、（174.13±43.05） μg/L和（212.43±64.25） μg/L,P<0.05】。结论聚乙二醇干扰素α-2a联合阿德福韦酯抗病毒疗效及改善HBeAg阳性CHB患者血清T淋巴细胞因子失衡,降低肝纤维化指标的作用优于单用阿德福韦酯者。

关键词: 慢性乙型肝炎, 聚乙二醇干扰素α, -2a, 阿德福韦酯, T淋巴细胞因子, 肝纤维化指标

Abstract: Objective To observe the efficacy of pegylated interferon α-2a combined with adefovir dipivoxil and their effects on serum T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B（CHB）. Methods 144 patients with CHB were randomly divided into observation group and control group with 72 cases in each group according to the inclusion orders. The patients in control group was given adefovir dipivoxil, and in the observation group was given pegylated interferon α-2a combined with adefovir dipivoxil. After 24-week treatment,the efficacy of treatment,and changes of serum IL-2,IL-10,IL-6 and INF-γ and PⅢP,LN,HA and Ⅳ-C in each group were recorded. Results At the end of 24 weeks of treatment,the negative rates of serum HBV DNA,HBeAg and HBeAg/anti-HBe seroconversion in observation group were 72.22%,58.33% and 41.67%,respectively,much higher than those in the control group（5.56%,22.22% and 20.83%,respectively,P<0.05 for all）;Compared with in control group,serum IL-2 and INF-γ in observation group were much higher [（2.18±1.26） pg/ml vs. （1.71±1.05） pg/ml,and （99.65±11.03） pg/ml vs. （85.70±11.82） pg/ml,P<0.05 for both],while serum IL-6 and IL-10 levels were much lower [（4.53±2.15） pg/ml vs. （5.47±2.25） pg/ml,and （15.42±9.39） pg/ml vs.（20.07±13.08） pg/ml,P<0.05 for both];Serum hepatic fibrosis indexes in observation group were much lower than those in the control group [HA （127.28±59.60） μg/L vs. （261.35±81.46） μg/L,LN （110.52±37.39） μg/L vs. （162.32±38.82） μg/L,Ⅳ-C （116.56±28.61） μg/L vs. （174.13±43.05） μg/L, PⅢ（163.65±64.38） μg/L vs. （212.43±64.25） μg/L,P<0.05 for all]. Conclusion Compared with single use of adefovir dipivoxil,pegylated interferon α-2a combined with adefovir dipivoxil have better antiviral effects and better improvement on T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B.

Key words: Chronic hepatitis B, Pegylated interferon α-2a, Adefovir dipivoxil, Cytokines, Hepatic fibrosis index

蔡乐斌, 陶娜. 聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者疗效及对血清细胞因子和肝纤维化指标的影响[J]. 实用肝脏病杂志, 2016, 19(5): 532-535.

Cai Lebin, Tao Na.. Efficacy of pegylated interferon α-2a combined with adefovir dipivoxil and their effects on serum T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 532-535.

参考文献

[1] Jun BG,Lee SH,Kim HS,et al. Predictive factors for sustained remission after discontinuation of antiviral therapy in patients with HBeAg-positive chronic hepatitis B. Korean J Gastroenterol,2016,67（1）:28-34.
[2] 任方元,李小丹. 阿德福韦酯联合拉米夫定治疗拉米夫定耐药的 HBeAg 阳性慢性乙型肝炎患者临床疗效观察. 实用肝脏病杂志,2014,17（2）：141-144.
[3] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[4] Fung S,Gordon SC,Krastev Z,et al. Tenofovir disoproxil fumarate in Asian or Pacific islander chronic hepatitis B patients with high viral load （≥9 log10 copies/ml）. Liver Int,2015,35（2）:422-428.
[5] Segovia MC,Chacra W,Gordon SC. Adefovir dipivoxil in chronic hepatitis B:history and current uses. Expert Opin Pharmacother,2012,13（2）:245-254.
[6] 肖作汉,孟冈,王立志,等. 聚乙二醇干扰素α-2a联合阿德福韦治疗HBeAg阳性慢性乙型肝炎疗效系统评价.实用肝脏病杂志,2015,18（1）：24-29.
[7] Gu J,Sun R,Shen S,et al. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pak J Pharm Sci,2015,28（4）:1493-1497.
[8] Boglione L,Cusato J,De Nicolò A,et al. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. J Viral Hepat,2015,22（3）:318-327.
[9] 任娜,闫杰,蔡晧东,等. 拉米夫定与阿德福韦酯初始联合治疗HBeAg阳性慢性乙型肝炎96周疗效观察. 国际病毒学杂志,2012,19（3）：113-117.
[10] Marcellin P,Wursthorn K,Wedemeyer H,et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol,2015,62（1）:41-47.
[11] 欧宏杰,吴晓鹭,刘家俊,等. 干扰素α联合阿德福韦酯对干扰素治疗无应答HBeAg阳性慢性乙型肝炎疗效观察. 中华临床感染病杂志,2013,6（2）：86-89.
[12] 于淑丽,郭超英.核苷（酸）类似物联合干扰素治疗HBeAg阳性慢性乙型肝炎120周的疗效随访.中华肝脏病杂志,2013,21（4）：267-270.
[13] Zhou P,Yang F,Wang J,et al. Improved efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine （Baltimore）,2015,94（17）:730.
[14] Govan L,Wu O,Xin Y,et al. Comparative effectiveness of antiviral treatment for hepatitis B:a systematic review and Bayesian network meta-analysis. Eur J Gastroenterol Hepatol,2015,27（8）:882-894.
[15] 陈新月,曹振环. 提高HBeAg阳性慢性乙型肝炎患者持久免疫控制的治疗策略. 中华肝脏病杂志,2013,21（7）：484-487.
[16] Lo AO,Wong VW,Wong GL,et al. Efficacy of tenofovir switch therapy for nucleos（t）ide-experienced patients with chronic hepatitis B. Aliment Pharmacol Ther,2015,41（11）:1190-1199.
[17] Singla B,Bhattacharyya R,Chakraborti A,et al. Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. Gene,2015,567（1）:22-30.
[18] Kamijo N,Matsumoto A. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion. World J Gastroenterol,2015,14;21（2）:541-548.
[19] 丁俊琪,姚建华,马陈斌,等. 慢性乙型肝炎患者血清HBeAg水平对阿德福韦酯抗病毒疗效的影响.实用肝脏病杂志,2015,18（4）：409-410.
[20] Bermingham SL,Hughes R,Fenu E,et al. Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positiveand HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health,2015,18（6）:800-809.